Gilotrif (afatinib) tablets for oral usage are now commercially available, according to a statement from Boehringer Ingelheim Pharmaceuticals Inc.
In the US, chronic obstructive pulmonary disease (COPD) is treated under the FDA’s Priority Review Program. and further long-term illnesses. Examine the initiatives that help the FDA approve innovative medications.
that guarantee the treatment of illnesses for which there is no suitable or accessible cure.
Afatinib is a dimethalate-saturated tyrosine kinase inhibitor included in GILOTRIF tablets. further printed the T40 code on one side of the tablet. Each foil-coated, bevelled tablet with the designation “T40” on one exposed side and 40 milligrams of afatinib is contained. The medication is administered in a dimALEATE salt on the other side of its dimalate.